标题:Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis
作者:Li,W.;Tai,Y.;Zhou,J.;Gu,W.;Bai,Z.;Zhou,T.;Zhong,Z.;McCue,P.A.;Sang,N.;Ji,J.-Y.;Kong,B.;Jiang,J.;Wang,C.
作者机构:[Li, W] Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China, Departments of Cancer Biology, Stem Cell 更多
通讯作者:Jiang, J
通讯作者地址:[Jiang, J]Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan 250100, Shandong, Peoples R China.
来源:Cell cycle
出版年:2012
卷:11
期:12
页码:2348-2358
DOI:10.4161/cc.20811
关键词:Cell death;Cell growth;Endometrial cancer;Lipogenesis;SREBP1
摘要:The aberrantly increased lipogenesis is a universal metabolic feature of proliferating tumor cells. Although most normal cells acquire the bulk of their fatty acids from circulation, tumor cells synthesize more than 90% of required lipids de novo. The sterol regulatory element-binding protein 1 (SREBP1), encoded by SREBF1 gene, is a master regulator of lipogenic gene expression. SREBP1 and its target genes are overexpressed in a variety of cancers; however, the role of SREBP1 in endometrial cancer is largely unknown. We have screened a cohort of endometrial cancer (EC) specimen for their lipogenic gene expression and observed a significant increase of SREBP1 target gene expression in cancer cells compared with normal endometrium. By using immunohistochemical staining, we confirmed SREBP1 protein overexpression and demonstrated increased nuclear distribution of SREBP1 in EC. In addition, we found that knockdown of SREBP1 expression in EC cells suppressed cell growth, reduced colonigenic capacity and slowed tumor growth in vivo. Furthermore, we observed that knockdown of SREBP1 induced significant cell death in cultured EC cells. Taken together, our results show that SREBP1 is essential for EC cell growth both in vitro and in vivo, suggesting that SREBP1 activity may be a novel therapeutic target for endometrial cancers.
收录类别:SCOPUS;SCIE
WOS核心被引频次:24
Scopus被引频次:32
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862837453&doi=10.4161%2fcc.20811&partnerID=40&md5=76b2fcb3d9c74d1989afd6656abf81b9
TOP